Protagonist Therapeutics (PTGX) Operating Income (2015 - 2026)

Protagonist Therapeutics has disclosed Operating Income across 12 years of filings, most recently posting -$3.6 million for Q1 2026.

• Operating Income for Q1 2026 came in at -$3.6 million, up 81.11% year-over-year; the trailing twelve-month figure through Mar 2026 was -$142.5 million (up 14.66% YoY), and the FY2025 annual result was -$158.1 million, down 369.49% from the prior year.
• Operating Income came in at -$3.6 million for Q1 2026 at Protagonist Therapeutics, up from -$50.4 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of $206.3 million in Q1 2024 to a low of -$67.4 million in Q4 2024.
• The 5-year median for Operating Income is -$38.3 million (2023), against an average of -$14.8 million.
• Peak annual rise in Operating Income reached 672.75% in 2024, while the deepest fall reached 167.31% in 2024.
• Protagonist Therapeutics' Operating Income stood at -$36.5 million in 2022, then surged by 374.18% to $100.1 million in 2023, then sank by 167.31% to -$67.4 million in 2024, then climbed by 25.27% to -$50.4 million in 2025, then surged by 92.76% to -$3.6 million in 2026.
• The last three Operating Income figures came in at -$3.6 million (Q1 2026), -$50.4 million (Q4 2025), and -$46.4 million (Q3 2025), per Business Quant data.